The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
The CAPRA‐S score: A straightforward tool for improved prediction of outcomes after radical prostatectomy
Open accessAbstract
BACKGROUND: The authors previously developed and validated the Cancer of the Prostate Risk Assessment (CAPRA) score to predict prostate cancer recurrence based on pretreatment clinical data. They aimed to develop a similar postsurgical score with improved accuracy via incorporation of pathologic data. METHODS: A total of 3837 prostatectomy patients in the Cancer of the Prostate Strategic Urologic Research Endeavor (CaPSURE™) national disease registry were analyzed. Cox regression was used to determine the predictive power of preoperative prostate‐specific antigen (PSA), pathologic Gleason score (pGS), surgical margins (SM), extracapsular extension (ECE), seminal vesicle invasion (SVI), and lymph node invasion (LNI). Points were assigned based on the relative weights of these variables in predicting recurrence. The new postsurgical score (CAPRA‐S) was tested and compared with a commonly cited nomogram with proportional hazards analysis, concordance (c) index, calibration plots, and decision‐curve analysis. RESULTS: Recurrence appeared in 16.8% of the men; actuarial progression‐free probability at 5 years was 78.0%. The CAPRA‐S was determined by adding up to 3 points for PSA, up to 3 points for pGS, 1 point each for ECE and LNI, and 2 points each for SM and SVI. The hazard ratio for each point increase in CAPRA‐S score was 1.54 (95% confidence interval, 1.49‐1.59), indicating a 2.4‐fold increase in risk for each 2‐point increase in score. The CAPRA‐S c‐index was 0.77, substantially higher than 0.66 for the pretreatment CAPRA score and comparable to 0.76 for the nomogram. The CAPRA‐S score performed better in both calibration and decision curve analyses. CONCLUSIONS: The CAPRA‐S offers good discriminatory accuracy, calibration, and ease of calculation for clinical and research settings. Cancer 2011;. © 2011 American Cancer Society.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A Proportional Hazards Model for the Subdistribution of a Competing Risk
Fine, J. P., & Gray, R. J. (1999) · Journal of the American Statistical Association · doi:10.1080/01621459.1999.10474144 · Cited by 14,290
Jemal, A., Siegel, R., Xu, J., & Ward, E. (2010) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.20073 · Cited by 12,596
Decision curve analysis: a novel method for evaluating prediction models
Vickers, A. J., & Elkin, E. B. (2006) · Medical Decision Making · doi:10.1177/0272989x06295361 · Cited by 6,341
Freedland, S. J., Humphreys, E. B., Mangold, L. A., Eisenberger, M., Dorey, F. J., Walsh, P. C., & Partin, A. W. (2005) · JAMA · doi:10.1001/jama.294.4.433 · Cited by 1,358
Thompson, I. M., Tangen, C. M., Paradelo, J., Lucia, M. S., Miller, G., Troyer, D., Messing, E., Forman, J., Chin, J., Swanson, G., et al. (2009) · Journal of Urology · doi:10.1016/j.juro.2008.11.032 · Cited by 1,227
Time Trends and Local Variation in Primary Treatment of Localized Prostate Cancer
Cooperberg, M. R., Broering, J. M., & Carroll, P. R. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.26.0133 · Cited by 1,006
Self-citationMessing, E. M., Manola, J., Yao, J., Kiernan, M., Crawford, D., Wilding, G., di'SantAgnese, P. A., & Trump, D. (2006) · The Lancet Oncology · doi:10.1016/s1470-2045(06)70700-8 · Cited by 893
Stephenson, A. J., Scardino, P. T., Kattan, M. W., Pisansky, T. M., Slawin, K. M., Klein, E. A., Anscher, M. S., Michalski, J. M., Sandler, H. M., Lin, D. W., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.08.9607 · Cited by 888
Cookson, M. S., Aus, G., Burnett, A. L., Canby-Hagino, E. D., D’Amico, A. V., Dmochowski, R. R., Eton, D. T., Forman, J. D., Goldenberg, S. L., Hernandez, J., et al. (2007) · Journal of Urology · doi:10.1016/j.juro.2006.10.097 · Cited by 844
COOPERBERG, M. R., PASTA, D. J., ELKIN, E. P., LITWIN, M. S., LATINI, D. M., Du CHANE, J., & CARROLL, P. R. (2005) · Journal of Urology · doi:10.1097/01.ju.0000158155.33890.e7 · Cited by 772
Self-citation
Cited by
Kerkmeijer, L. G. W., Groen, V. H., Pos, F. J., Haustermans, K., Monninkhof, E. M., Smeenk, R. J., Kunze-Busch, M., de Boer, J. C. J., van der Voort van Zijp, J., van Vulpen, M., et al. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.20.02873 · Cited by 531
High-risk prostate cancer—classification and therapy
Chang, A. J., Autio, K. A., Roach, M., & Scher, H. I. (2014) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2014.68 · Cited by 500
Parker, C. C., Clarke, N. W., Cook, A. D., Kynaston, H. G., Petersen, P. M., Catton, C., Cross, W., Logue, J., Parulekar, W., Payne, H., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)31553-1 · Cited by 410
Vale, C. L., Fisher, D., Kneebone, A., Parker, C., Pearse, M., Richaud, P., Sargos, P., Sydes, M. R., Brawley, C., Brihoum, M., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)31952-8 · Cited by 404
Cooperberg, M. R., Simko, J. P., Cowan, J. E., Reid, J. E., Djalilvand, A., Bhatnagar, S., Gutin, A., Lanchbury, J. S., Swanson, G. P., Stone, S., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.46.4396 · Cited by 351
Self-citationKarnes, R. J., Bergstralh, E. J., Davicioni, E., Ghadessi, M., Buerki, C., Mitra, A. P., Crisan, A., Erho, N., Vergara, I. A., Lam, L. L., et al. (2013) · Journal of Urology · doi:10.1016/j.juro.2013.06.017 · Cited by 325
Prensner, J. R., Zhao, S., Erho, N., Schipper, M., Iyer, M. K., Dhanasekaran, S. M., Magi-Galluzzi, C., Mehra, R., Sahu, A., Siddiqui, J., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)71113-1 · Cited by 264
Mehra, R., Shi, Y., Udager, A. M., Prensner, J. R., Sahu, A., Iyer, M. K., Siddiqui, J., Cao, X., Wei, J., Jiang, H., et al. (2014) · Neoplasia · doi:10.1016/j.neo.2014.11.006 · Cited by 95
“Lastly, integration of SChLAP1 ISH with established multifactor clinical nomograms, such as the Cancer of the Prostate Risk Assessment (CAPRA-S) score [27,28], will be important to assess whether SChLAP1 staining improves the performance of these risk-stratification algorithms.”
Metadata
- Authors
- Cooperberg, M. R., Hilton, J. F., & Carroll, P. R.
- Venue
- Cancer
- Publisher
- Wiley
- Published
- 2011-06-03
- Volume
- 117
- Issue
- 22
- Pages
- 5039-5046
- ISSN
- 0008-543X (ISSN-L)
- 1097-0142
- OpenAlex
- W2041120035
- Cited by
- 457
- References
- 28
- FWCI
- 16.83
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.